scispace - formally typeset
Journal ArticleDOI

Converting-enzyme inhibitors in the treatment of hypertension.

Gordon H. Williams
- 08 Dec 1988 - 
- Vol. 319, Iss: 23, pp 1517-1525
TLDR
In 1982, Vidt and colleagues reviewed the pharmacokinetics, mechanisms of action, and therapeutic usefulness of captopril, the first of a new class of antihypertensives, converting-enzyme inhibitor, and found it to be of high therapeutic usefulness.
Abstract
IN 1982, Vidt and colleagues reviewed the pharmacokinetics, mechanisms of action, and therapeutic usefulness of captopril, the first of a new class of antihypertensives, converting-enzyme inhibitor...

read more

Citations
More filters
Journal ArticleDOI

Drugs targeting the renin–angiotensin–aldosterone system

TL;DR: Drugs that inhibit or antagonize components of the renin–angiotensin–aldosterone system are addressing this deficiency by targeting both blood pressure and related structural and functional abnormalities of the heart and blood vessels, thus preventing target-organ damage and related cardiovascular events.
Journal ArticleDOI

Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology.

TL;DR: The ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Maria Angeles Alonso Garcia (Spain), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), Martin Cowie (UK), Veronica Dean (France, Jaap Deckers (The Netherlands), Enrique Fernandez Burgos (Spain) as mentioned in this paper, John Lekakis (Greece), Bertil Lindahl (Sweden), Gianfranco Mazzotta (Italy).
Journal ArticleDOI

Angiotensin-converting enzyme inhibitor fetopathy.

TL;DR: It is recommended that ACE inhibitors not be used in pregnancy, particularly in the second and third trimesters, because of the debilitating and lethal nature of the fetal damage when it occurs.
Journal ArticleDOI

Functional and Biochemical Analysis of Angiotensin II–Forming Pathways in the Human Heart

TL;DR: The authors' studies indicate an incomplete ACE inhibition in human heart tissue after chronic ACE inhibitor therapy, and drugs such as renin inhibitors and Ang II receptor blockers might be able to induce a more complete blockade of the renin-angiotensin system, providing a more efficacious therapy.
References
More filters
Journal ArticleDOI

Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents

TL;DR: A hypothetical model of the active site of angiotensin-converting enzyme, based on known chemical and kinetic properties of the enzyme, has enabled a new class of potent and specific inhibitors, carboxyalkanoyl and mercaptoalkanoysl derivatives of proline, to be designed.
Journal ArticleDOI

The Effects of Antihypertensive Therapy on the Quality of Life

TL;DR: It is shown that antihypertensive agents have different effects on the quality of life and that these can be meaningfully assessed with available psychosocial measures.
Journal ArticleDOI

The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure

TL;DR: This report updates findings of previous reports in several respects: it broadens the step-care approach to provide more flexibility for clinicians; encourages greater patient involvement in the treatment program; emphasizes a consideration of the quality of life in the management of patients; and addresses the cost of care.
Journal ArticleDOI

The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

TL;DR: A number of clinical studies have been performed in an attempt to dissect the particular component or components of the diabetic state responsible for these early elevations in glomerular filtration rate, and no single factor appears to account fully for this phenomenon.
Journal ArticleDOI

Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney.

TL;DR: A variety of mechanisms have been postulated to account for captopril-based renal failure and these include angiotensin-converting-enzyme inhibitor-like mechanisms, cell reprograming, and “spatially masked” mechanisms.
Related Papers (5)